We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Sprayable Powder-Type Hemostatic Agent Stops Bleeding in One Second

By HospiMedica International staff writers
Posted on 12 Jan 2026

Uncontrolled bleeding remains the leading cause of preventable death from injuries. More...

Rapid blood loss can be fatal within minutes, especially when wounds are deep, irregular, or difficult to compress. Existing hemostatic patches are often ineffective in such scenarios and can be impractical in harsh environments. New research now presents a spray-on powder that can stop bleeding within one second, offering a potential breakthrough for emergency care, especially in medically underserved areas.

An interdisciplinary team of researchers at the Korea Advanced Institute of Science and Technology (Daejeon, South Korea) has designed a powder-type hemostatic agent optimized for emergency medicine. The agent rapidly transforms into a strong hydrogel barrier upon contact with blood, enabling immediate wound sealing without complex preparation.

The researchers focused on overcoming the limitations of flat, patch-based hemostatic products by creating a free-flowing powder suitable for deep and irregular wounds. The formulation, known as AGCL powder, combines naturally derived materials including alginate and gellan gum, which undergo ultra-fast gelation in the presence of calcium ions, and chitosan, which enhances biological clotting through interaction with blood components. The powder’s internal three-dimensional structure was engineered to maximize blood absorption and adhesion.

The AGCL powder gelled within approximately one second after application and absorbed more than seven times its own weight in blood. It demonstrated strong sealing performance under high-pressure bleeding, with adhesive strength exceeding 40 kPa, outperforming commercial hemostatic agents. Safety testing showed low hemolysis, high cell viability, and strong antibacterial activity. In animal models, the powder reduced bleeding time, promoted tissue regeneration, and supported normal organ recovery without systemic toxicity.

The hemostatic agent maintained performance for up to two years under room temperature and high-humidity conditions, making it suitable for storage and rapid deployment in resource-limited settings. The technology could be used widely in emergency medicine, trauma care, and humanitarian response, where rapid bleeding control is critical.

Related Links:
KAIST


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.